What Happened?
San Diego, CA-based Sorrento Therapeutics Appointed Pam Fettu as Senior Human Resource Executive
Date of management change: September 15, 2014
San Diego, CA-based Sorrento Therapeutics Appointed Pam Fettu as Senior Human Resource Executive
Sorrento is an oncology company developing new treatments for cancer and associated pain. Sorrento recently announced that NantPharma acquired the rights to Cynviloq™, which completed a successful TRIBECA study. Sorrento is also developing resiniferatoxin (RTX), a non-opiate TRPV1 agonist currently in a Phase 1/2 study at the NIH to treat terminal cancer patients suffering from intractable pain. In December 2014, Sorrento and NantWorks formed a global joint venture, now called Nantibody, to focus on immunotherapies for cancer. Also in December 2014, Sorrento and Conkwest, Inc., a privately-held immuno-oncology company developing proprietary Neukoplast,® a Natural Killer (NK) cell-line based therapy, entered into an agreement to jointly develop CAR.TNK™ (Chimeric Antigen Receptor Tumor-attacking Neukoplast) immunotherapies for the treatment of cancer and infectious diseases. In March 2015, Sorrento entered into a global collaboration with NantCell, a NantWorks company, to discover and develop immunotherapies against tumor neo-epitopes.
Pam Fettu is Senior Human Resource Executive at Sorrento Therapeutics. Previously, Pam held various senior HR leadership roles in the industry.
Press Release
Other IT executives who recently changed jobs as well: Bhargava Rishi, Page Andy, Senaratne Jeanne, Tucker Kelley, Najjar Joe, Hull Kieran, Ottens Traci, Strazdins Linda, Ptasinski Christina, Duarte Ernesto, Helthall Jeff
You can find the full directory of IT executives here.
How would you like to connect with 15,000+ IT executives in charge of $ millions in IT budgets? Find details here.